Ekta Kapadia

机构：Merck & Co., Inc., Rahway, NJ, USA (United States)

发表论文 36 篇 · 总被引 1024 次 · h-index 10

代表论文

Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study (2021 · The Lancet Oncology · 被引 562)
KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBC (2020 · Future Oncology · 被引 96)
Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial (2024 · The Lancet Oncology · 被引 95)
Pembrolizumab (pembro) for the treatment of patients with Bacillus Calmette-Guérin (BCG) unresponsive, high-risk (HR) non–muscle-invasive bladder cancer (NMIBC): Over two years follow-up of KEYNOTE-057. (2020 · Journal of Clinical Oncology · 被引 30)
Phase 3 KEYNOTE-992 study of pembrolizumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with muscle-invasive bladder cancer (MIBC). (2024 · Journal of Clinical Oncology · 被引 14)
Phase III study of pembrolizumab (pembro) plus chemoradiotherapy (CRT) versus CRT alone for patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-992. (2020 · Journal of Clinical Oncology · 被引 14)